To the Editor:Transcatheter aortic valve replacement(TAVR)has become an established treatment for patients with severe aortic stenosis(AS)at all levels of surgical risk.^([1,2])With the exploration of TAVR and technol...To the Editor:Transcatheter aortic valve replacement(TAVR)has become an established treatment for patients with severe aortic stenosis(AS)at all levels of surgical risk.^([1,2])With the exploration of TAVR and technological developments,TAVR is an alternative for patients with intermediate or low surgical risk.^([3])There are some studies regarding gender differences in TAVR,but there are few studies on it in Asia.^([4])However,the studies of outcomes based on gender differences in TVAR are still lacking,especially in China and other Asian countries.展开更多
To the Editor:Approximately 2%of people>65 years old have aortic stenosis(AS).[1]Without intervention,AS is a rapidly progressive valvular heart disease with a 2-year mortality of 50%.[1]Since the first transcathet...To the Editor:Approximately 2%of people>65 years old have aortic stenosis(AS).[1]Without intervention,AS is a rapidly progressive valvular heart disease with a 2-year mortality of 50%.[1]Since the first transcatheter aortic valve replacement(TAVR)was performed by Cribier et al[2]in 2002,TAVR has been suggested to be non-inferior in AS patients of various risk stratifications.Post-TAVR complications are essential in predicting patient survival and improving quality of life,especially with the procedure being performed in an increasing population of low-risk patients.[3]Among them,myocardial infarction(MI)is a rare but life-threatening complication usually caused by the obstruction of coronary ostia.[1]In comparison,peri-procedural myocardial injury,primarily characterized by the elevation of cardiac markers,is a relatively common complication of TAVR.Although recent studies have demonstrated promising results of cardiac markers in predicting cardiovascular adverse events,the impact of peri-procedural myocardial injury on short-term and long-term mortality has yet to be established.展开更多
基金supported by grants from the West China Hospital“1·3·5”Discipline of Excellence Project-“Mechanisms of aortic stenosis and the clinical applications”,National Natural Science Foundation of China(No.82001899)the National Natural Science Foundation of China(No.81901825).
文摘To the Editor:Transcatheter aortic valve replacement(TAVR)has become an established treatment for patients with severe aortic stenosis(AS)at all levels of surgical risk.^([1,2])With the exploration of TAVR and technological developments,TAVR is an alternative for patients with intermediate or low surgical risk.^([3])There are some studies regarding gender differences in TAVR,but there are few studies on it in Asia.^([4])However,the studies of outcomes based on gender differences in TVAR are still lacking,especially in China and other Asian countries.
基金supported by the National Natural Science Foundation of China(No.82001899)West China Hospital"1·3·5"Discipline of Excellence Project—"Mechanisms of aortic stenosis and the clinical applications".
文摘To the Editor:Approximately 2%of people>65 years old have aortic stenosis(AS).[1]Without intervention,AS is a rapidly progressive valvular heart disease with a 2-year mortality of 50%.[1]Since the first transcatheter aortic valve replacement(TAVR)was performed by Cribier et al[2]in 2002,TAVR has been suggested to be non-inferior in AS patients of various risk stratifications.Post-TAVR complications are essential in predicting patient survival and improving quality of life,especially with the procedure being performed in an increasing population of low-risk patients.[3]Among them,myocardial infarction(MI)is a rare but life-threatening complication usually caused by the obstruction of coronary ostia.[1]In comparison,peri-procedural myocardial injury,primarily characterized by the elevation of cardiac markers,is a relatively common complication of TAVR.Although recent studies have demonstrated promising results of cardiac markers in predicting cardiovascular adverse events,the impact of peri-procedural myocardial injury on short-term and long-term mortality has yet to be established.
